MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral

Nature Medicine

Volumn 4, Issue 3, 1998, Pages 315-320

  Apostolopoulos, Vasso ^a   Osinski, Carla ^a   Mckenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; EPITOPE; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHICKEN; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMORAL IMMUNITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN-PRESENTING CELLS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CANCER VACCINES; CROSS REACTIONS; DISACCHARIDES; EPITOPES; FEMALE; GALACTOSYLTRANSFERASES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; MANNANS; MICE; MICE, MUTANT STRAINS; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; GALLUS GALLUS; ORYCTOLAGUS CUNICULUS; RODENTIA;

EID: 0031889940     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0398-315     Document Type: Article

References (24)

1. Singer, A. News: Time and truth for cancer vaccines - a new generation. J. Natl. Cancer Inst. 86, 330-330 (1994).
2. Kawakami, Y. et al. Cloning of the gene coding for a shared human-melanoma antigen recognized by autologous T-cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515-3519 (1994).
3. Disis, M.L., Smith, J.W., Murphy, A.E., Chen, W. & Cheever, M.A. In vitro generation of human CTL specific for peptides derived from the Her-2/neu protooncogene protein. Cancer Res. 54, 1071-1076 (1994).
4. Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. & Sherman, L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92, 11993-11997 (1995).
5. Schendel, D.J. & Gansbacher, B. Tumor specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha Interferon treatment. Cancer Res. 53, 4020-4025 (1993).
6. Apostolopoulos, V., McKenzie, I.F.C. & Pietersz, G.A. Breast cancer immunotherapy - Current status and future prospects. Immunol. Cell Biol. 74, 457-464 (1996).
7. Apostolopoulos, V., Xing, P.X. & McKenzie, I.F.C. Murine immune response to cells transfected with human MUC1: Immunization with cellular and synthetic antigens. Cancer Res. 54, 5186-5193 (1994).
8. Apostolopoulos, V., Pietersz, G.A. & McKenzie, I.F.C. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14, 930-938 (1996).
9. 2 immune responses. Proc. Natl. Acad. Sci. USA 92, 10128-10132 (1995).
10. Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. invest. 100, 2738-2792 (1997).
11. Vaughan, H.A. et al. Recognition of an octapeptide sequence by multiple Galα(1, 3)Gal-binding proteins. Xenotransplantation 3, 18-23 (1996).
12. Sandrin, M.S., Vaughan, H.A., Xing, P.X. & McKenzie, I.F.C. Natural human antiGalα(1,3)Gal antibodies react with human mucin peptides. Glycoconj. J. 14, 97-105 (1997).
13. Sandrin, M.S., Vaughan, H.A., Dabkowski, P.L. & McKenzie, I.F.C. Anti-pig antibodies in human serum predominantly with Galα(1, 3)Gal epitopes. Proc. Natl. Acad. Sci. USA 90, 11391-11395 (1995).
14. Vaughan, H.A., Loveland, B.E. & Sandrin, M.S. Galα(1, 3)Gal is the major xenoepitope expressed on pig endothelial cells recognised by naturally occurring cytotoxic antibodies. Transplantation 58, 879-884 (1994).
15. McKenzie, I.F.C., et al. Distribution of the major xenoantigens (Galα(1, 3)Gal) for pig to human xenografts. Transplant Immunol. 2, 81-86 (1994).
16. Galili, U. & La Temple, C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol. Today 18, 281-285 (1997).
17. Celis, E., Abraham, K.G. & Miller, R.W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 7, 563-568 (1987).
18. Amigorena, S. et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256, 1801-1812 (1992).
19. Bouige, P., Iscaki, S., Cosson, A. & Pillot, J. Molecular analysis of the modulator/factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Immunol. Med. Microbiol. 13, 71-79 (1996).
20. Heijnen, I.A. et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97, 331-338 (1996).
21. Molina, H., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93, 3357-3361 (1996).
22. Lefkovits, I., & Waldmann, H. Limiting dilution analysis of the cells of the immune system. I. The clonal basis of the immune response. Immunol. Today 5, 265-272 (1984).
23. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J. Immunol. 126, 1614-1619 (1981).
24. Fazekas de St. Groth, S. The evaluation of limiting dilution assays [review]. J. Immunol. Methods 49, R11-R23 (1982).